Literature DB >> 16465658

Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.

Takashi Matsushita1, Minoru Hasegawa, Yasuhito Hamaguchi, Kazuhiko Takehara, Shinichi Sato.   

Abstract

OBJECTIVE: Skin sclerosis that progresses in the earlier disease phase in systemic sclerosis (SSc) spontaneously regresses thereafter. We investigated the relationship between changes of the serum cytokine profile and changes in skin fibrosis in patients with SSc.
METHODS: Serum cytokine levels were examined by ELISA using 180 sera samples from 26 patients with early diffuse cutaneous SSc (dcSSc) with mean disease duration of 2.1 years. The mean followup period was 4.9 years (range 2-8). Cytokine mRNA expression in the affected skin was quantified by real-time reverse transcription-polymerase chain reaction.
RESULTS: Modified Rodnan total skin thickness score decreased after 2, 4, and 6 years compared to that at first visit. Serum levels of the Th2 cytokines interleukin 6 (IL-6) and IL-10 and monocyte chemotactic protein-1 (MCP-1) were higher at first evaluation compared to healthy controls, while IL-4 levels were normal. Levels of all Th2 cytokines generally decreased as skin sclerosis regressed. Conversely, levels of serum IL-12, a Th1-inducing cytokine, were lower at first visit relative to controls, but increased by roughly 15-fold after 6 years to significantly higher levels than controls. Surviving dcSSc patients exhibited elevated IL-12 levels compared to deceased patients. Serum levels of transforming growth factor-ss1 (TGF-ss1), a fibrogenic cytokine, increased throughout followup, with slightly decreased levels at later timepoints. IL-12 mRNA expression was upregulated in affected skin from patients with late-stage dcSSc, while TGF-ss1 and MCP-1 expression was downregulated.
CONCLUSION: These results suggest that a shift from Th2 to Th1 response correlates with improvement in skin fibrosis in SSc, and that IL-12 level is a serologically useful marker for disease activity and prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16465658

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  39 in total

1.  A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations.

Authors:  Lara Bossini-Castillo; Jose-Ezequiel Martin; Jasper Broen; Olga Gorlova; Carmen P Simeón; Lorenzo Beretta; Madelon C Vonk; Jose Luis Callejas; Ivan Castellví; Patricia Carreira; Francisco José García-Hernández; Mónica Fernández Castro; Marieke J H Coenen; Gabriela Riemekasten; Torsten Witte; Nicolas Hunzelmann; Alexander Kreuter; Jörg H W Distler; Bobby P Koeleman; Alexandre E Voskuyl; Annemie J Schuerwegh; Øyvind Palm; Roger Hesselstrand; Annika Nordin; Paolo Airó; Claudio Lunardi; Raffaella Scorza; Paul Shiels; Jacob M van Laar; Ariane Herrick; Jane Worthington; Christopher Denton; Filemon K Tan; Frank C Arnett; Sandeep K Agarwal; Shervin Assassi; Carmen Fonseca; Maureen D Mayes; Timothy R D J Radstake; Javier Martin
Journal:  Hum Mol Genet       Date:  2011-11-10       Impact factor: 6.150

Review 2.  Recent advances on pathogenesis and therapies in systemic sclerosis.

Authors:  Norihito Yazawa; Manabu Fujimoto; Kunihiko Tamaki
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

Review 3.  Vasculopathy in scleroderma.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

Review 4.  The pathogenesis of systemic sclerosis revisited.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 5.  Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.

Authors:  Luca Cantarini; Donato Rigante; Antonio Vitale; Salvatore Napodano; Lazaros I Sakkas; Dimitrios P Bogdanos; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

6.  Spontaneous skin regression and predictors of skin regression in Thai scleroderma patients.

Authors:  Chingching Foocharoen; Ajanee Mahakkanukrauh; Siraphop Suwannaroj; Ratanavadee Nanagara
Journal:  Clin Rheumatol       Date:  2011-04-12       Impact factor: 2.980

7.  Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis.

Authors:  Takashi Yamashita; Yoshihide Asano; Takashi Taniguchi; Kouki Nakamura; Ryosuke Saigusa; Shunsuke Miura; Tetsuo Toyama; Takehiro Takahashi; Yohei Ichimura; Ayumi Yoshizaki; Maria Trojanowska; Shinichi Sato
Journal:  J Invest Dermatol       Date:  2016-10-21       Impact factor: 8.551

8.  Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein.

Authors:  Steven O'Reilly; Marzena Ciechomska; Rachel Cant; Jacob M van Laar
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

9.  Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.

Authors:  Kathryn S Torok; Katherine Kurzinski; Christina Kelsey; Jonathan Yabes; Kelsey Magee; Abbe N Vallejo; Thomas Medsger; Carol A Feghali-Bostwick
Journal:  Semin Arthritis Rheum       Date:  2015-06-17       Impact factor: 5.532

10.  Increased circulating fibrinogen-like protein 2 in patients with systemic sclerosis.

Authors:  Koichi Yanaba; Yoshihide Asano; Shinji Noda; Kaname Akamata; Naohiko Aozasa; Takashi Taniguchi; Takehiro Takahashi; Yohei Ichimura; Tetsuo Toyama; Hayakazu Sumida; Yoshihiro Kuwano; Yayoi Tada; Makoto Sugaya; Takafumi Kadono; Shinichi Sato
Journal:  Clin Rheumatol       Date:  2012-09-16       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.